ANI Pharmaceuticals Inc (ANIP)

Return on total capital

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	-12,831	3,627	47,321	51,679	46,519	42,778	27,310	3,362	-25,064	-53,223	-56,915	-53,573	-32,512	-8,705	-1,499	-5,702	-16,064	-21,389	-16,667	4,094
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	428,530	430,798	455,760	451,963	432,749	454,711	434,472	339,482	338,540	336,675	336,958	346,094	358,740	191,403	191,917	203,712	195,700	195,100	191,344	201,171
Return on total capital		-2.99%	0.84%	10.38%	11.43%	10.75%	9.41%	6.29%	0.99%	-7.40%	-15.81%	-16.89%	-15.48%	-9.06%	-4.55%	-0.78%	-2.80%	-8.21%	-10.96%	-8.71%	2.04%

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-12,831K ÷ ($—K + $428,530K)
= -2.99%

ANI Pharmaceuticals Inc's return on total capital has demonstrated significant fluctuations over the past few years. The ratio was negative for most quarters up until the end of June 2023, indicating that the company's capital utilization was not generating sufficient returns. However, beginning in the first quarter of 2024, the return on total capital started to improve, reaching double-digit percentages by the end of that year. This upward trend suggests a potential enhancement in the company's efficiency in utilizing its total capital to generate profits. ANI Pharmaceuticals Inc may have implemented strategic changes or operational improvements that positively impacted its return on total capital during this period.